Clinical investigation of hepatitis B immunoglobulins

Current effective version

PDF iconAdopted guideline

Reference numberCHMP/BPWP/585257/2009
Effective from01/02/2016
KeywordsHepatitis B immunoglobulins, immunoprophylaxis of hepatitis B, liver transplantation hepatitis B induced liver failure
DescriptionThis document describes the information to be included in a marketing authorisation application for a hepatitis B immunoglobulin. It covers biological data, pharmacokinetics, clinical trials and patient follow-up.

Document history

First version

Current version

PDF iconAdopted guideline

PDF iconOverview of comments

PDF iconDraft guideline

In operation: 01/02/2016–present

Published: 24/05/2015

Published: 03/12/2012

Related content

How useful was this page?

Add your rating